Satralizumab

CHEMBL3833307 Phase 4 Approved Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Satralizumab is a humanized anti-interleukin-6 receptor (anti-IL-6R) monoclonal antibody used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody-positive patients. By blocking IL-6 signaling, it reduces B-cell-mediated autoimmune pathology and decreases production of pathogenic AQP4-specific antibodies. It is administered subcutaneously and has demonstrated reduction in relapse rates in clinical trials.

Therapeutic Areas

Immunology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Satralizumab is a humanized anti-interleukin-6 receptor (anti-IL-6R) monoclonal antibody used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody-positive patients. By blocking IL-6 signaling, it reduces B-cell-mediated autoimmune pathology and decreases production of pathogenic AQP4-specific antibodies. It is administered subcutaneously and has demonstrated reduction in relapse rates in clinical trials.

Yes, Satralizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3833307. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Looking for patient-friendly information?

Satralizumab on PillFYI

Quick Data

Synonyms: 1

External Links

ChEMBL CHEMBL3833307

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.